Delving into the Latest Updates on Oncolytic measles virus encoding thyroidal sodium iodide symporter infected mesenchymal stem cells(Mayo Clinic) with Synapse

Overview

Basic Info

Drug Type

Mesenchymal stem cell therapy

Synonyms-

Target-

Action-

Mechanism

Cell replacements

Therapeutic Areas

NeoplasmsDigestive System DisordersEndocrinology and Metabolic Disease+ [3]

Active Indication

Endometrioid carcinoma ovaryFallopian Tube Clear Cell AdenocarcinomaMucinous Adenocarcinoma+ [17]

Inactive Indication-

Originator Organization

Mayo Clinic

Active Organization

Mayo Clinic

Inactive Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

This randomized phase II trial studies how well oncolytic measles virus encoding thyroidal sodium iodide symporter (MV-NIS) compared to investigator's choice chemotherapy works in treating patients with ovarian, fallopian, or peritoneal cancer. Measles virus, which has been changed in a certain way, may be able to kill tumor cells without damaging normal cells.

Start Date13 Mar 2015

Sponsor / Collaborator

Mayo Clinic

NCT02068794

/ Active, not recruitingPhase 1/2IIT

Phase I/II Trial of Intraperitoneal Administration of Adipose Tissue Derived Mesenchymal Stem Cells Infected With a NIS-Expressing Derivative Manufactured From a Genetically Engineered Strain of Measles Virus in Patients With Recurrent Ovarian Cancer

This phase I/II trial studies the side effects and best dose of oncolytic measles virus encoding thyroidal sodium iodide symporter (MV-NIS) infected mesenchymal stem cells and to see how well it works in treating patients with ovarian, primary peritoneal or fallopian tube cancer that has come back. Mesenchymal stem cells may be able to carry tumor-killing substances directly to ovarian, primary peritoneal and fallopian tube cancer cells.

Start Date25 Apr 2014

Sponsor / Collaborator

Mayo Clinic

[+1]

100 Clinical Results associated with Oncolytic measles virus encoding thyroidal sodium iodide symporter infected mesenchymal stem cells(Mayo Clinic)

Login to view more data

100 Translational Medicine associated with Oncolytic measles virus encoding thyroidal sodium iodide symporter infected mesenchymal stem cells(Mayo Clinic)

Login to view more data

100 Patents (Medical) associated with Oncolytic measles virus encoding thyroidal sodium iodide symporter infected mesenchymal stem cells(Mayo Clinic)

Login to view more data

100 Deals associated with Oncolytic measles virus encoding thyroidal sodium iodide symporter infected mesenchymal stem cells(Mayo Clinic)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Endometrioid carcinoma ovary	Phase 2	United States	Mayo Clinic	13 Mar 2015
Ovarian Carcinosarcoma	Phase 2	United States	Mayo Clinic	13 Mar 2015
Ovarian mixed epithelial carcinoma	Phase 2	United States	Mayo Clinic	13 Mar 2015
Ovarian Serous Adenocarcinoma	Phase 2	United States	Mayo Clinic	13 Mar 2015
Platinum-Resistant Ovarian Carcinoma	Phase 2	United States	Mayo Clinic	13 Mar 2015
Primary Peritoneal Serous Adenocarcinoma	Phase 2	United States	Mayo Clinic	13 Mar 2015
Recurrent ovarian cancer	Phase 2	United States	Mayo Clinic	13 Mar 2015
Recurrent Primary Peritoneal Carcinoma	Phase 2	United States	Mayo Clinic	13 Mar 2015
Transitional Cell Carcinoma	Phase 2	United States	Mayo Clinic	13 Mar 2015
Brenner Tumor	Phase 2	United States	Mayo Clinic	25 Apr 2014